Pfizer's Talzenna/Xtandi combo meets phase III goals, significantly delaying disease progression in HRR-mutated metastatic castration-sensitive prostate cancer patients.
Scientists have identified a novel two-pronged treatment method, offering significant potential for patients battling advanced prostate cancer. Experts at The Institute of Cancer Research, London, ...
Pfizer (PFE) stock is in focus as Xtandi, marketed with Astellas (ALPMF), and cancer drug Talzenna succeed in a Phase 3 trial for prostate cancer. Read more here.
A surge in the rate of incurable prostate cancer cases could be a sign to rethink Canada’s stance on screening for one of the most common diseases for men, according to new research. The new study, ...
A “search and destroy” treatment has been found to halt tumours in some men with incurable prostate cancer. The early-stage trial investigated a form of radiotherapy on patients who had stopped ...
Discover six prostate cancer companies advancing the next generation of therapies for all stages of the disease.
The FDA's cancer advisors will discuss AstraZeneca’s application for the oral SERD camizestrant in breast cancer and the AKT ...
Explore cancer drug resistance and its significant impact on treatment options and patient outcomes in modern cancer therapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results